Astellas Pharma, Inc. is launching a new drug for a common symptom of menopause, a category that has lacked innovation, following the US Food and Drug Administration’s approval of Veozah (fezolinetant) for moderate to severe vasomotor symptoms (VMS) due to menopause. Veozah is a first-in-class neurokinin 3 (NK3) receptor antagonist that is the first nonhormonal therapy approved to treat VMS due to menopause.
Astellas’ Veozah Is First-In-Class Treatment For Vasomotor Symptoms
Veozah received approval from the US FDA for a common symptom of menopause, a therapeutic area that has lacked pharmaceutical advancements.
